LDLR

Across TCGA pan-cancer cohorts, LDLR mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated LDLR data layer compared with 24 for mass-spec protein and 11 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher LDLR mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated LDLR expression acts as an unfavorable survival marker.

PDAC, LUAD, and LSCC are the cancer types where LDLR mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.706	0.875	.027	5	view →
LUAD	DFS	Quartile	III,IV	0.321	0.696	.024	4	view →
LSCC	OS	Median	All	0.793	1.000	.025	2	view →
UCEC	DFS	Quartile	All	0.842	1.000	.029	2	view →
CCRCC	DFS	Quartile	II,III,IV	0.599	1.000	.024	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

LDLR–PDAC (DFS)

Open the PDAC breakdown →